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Introduction: Purified prothrombin complex concentrate (PCC) is increasingly used as hemostatic therapy for
trauma-induced coagulopathy (TIC). However, the impact of PCC administration on coagulation status among
patients with TIC has not been adequately investigated.
Methods: In this observational, descriptive study, data relating to thrombin generation were obtained from
plasma samples gathered prospectively from trauma patients upon emergency room (ER) admission and over
the following 7 days. Standard coagulation tests, including measurement of antithrombin (AT) and fibrinogen,
were performed. Three groups were investigated: patients receiving no coagulation therapy (NCT group),
patients receiving fibrinogen concentrate only (FC group), and patients treated with PCC and fibrinogen
concentrate (FC-PCC group).
Results: The study population (77 patients) was predominantly male (84.4%); mean age was 40 ± 15 years and
mean injury severity score was 25.6 ± 12.7. There were no significant differences between the three study groups
in thrombin-related parameters upon ER admission. Endogenous thrombin potential (ETP) was significantly
higher in the FC-PCC group compared with the NCT group on days 1 to 4 and the FC group on days 1 to 3. AT
levels were significantly lower in the FC-PCC group from admission until day 3 (versus FC group) or day 4 (versus
NCT group). Fibrinogen increased over time, with no significant between-group differences after ER admission.
Despite ETP being higher, prothrombin time and activated partial thromboplastin time were significantly
prolonged in the FC-PCC group from admission until day 3 to 4.
Conclusions: Treatment with PCC increased ETP for several days, and patients receiving PCC therapy had low
AT concentrations. These findings imply a potential pro-thrombotic state not reflected by standard coagulation
tests. This is probably important given the postoperative acute phase increase in fibrinogen levels, although
studies with clinical endpoints are needed to ascertain the implications for patient outcomes. We recommend
careful use of PCC among trauma patients, with monitoring and potentially supplementation of AT.* Correspondence: herbert.schoechl@auva.at
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Approximately one quarter to one third of all trauma
patients present with coagulopathy detectable by standard
coagulation tests such as prothrombin time (PT) or acti-
vated partial thromboplastin time (aPTT) [1,2]. Early and
aggressive coagulation therapy is proven to be beneficial
in these patients [3,4]. In most trauma centers worldwide
fresh frozen plasma (FFP) is used first line to increase
hemostatic capacity [4]. FFP contains both coagulation
factors and inhibitors, but the thawing process often
results in a substantial time delay before treatment can
be started and only high-volume trauma centers store
pre-thawed plasma for immediate use [5-7]. Concentra-
tions of coagulation factors in FFP are determined by the
donor levels, meaning considerable variability between
units [8]. Moreover, physiological levels limit the extent to
which patients’ coagulation factor levels can be raised by
FFP [9].
Coagulation factor concentrates such as purified human
fibrinogen concentrate and prothrombin complex concen-
trate (PCC) are considered as potential alternatives to FFP
[10,11]. These substances are immediately available and
contain well-defined quantities of coagulation proteins.
Coagulation management based on infusion of concen-
trates under guidance from point-of-care coagulation
monitoring (thrombelastography or thromboelastometry)
has been proposed [12]. Fibrinogen concentrate is adminis-
tered first line to correct low levels of fibrinogen, which are
rapidly detectable by impaired fibrin-based clot formation
(FIBTEM assay or functional fibrinogen assay) [13-16].
Among patients with adequate fibrinogen levels but
persistent bleeding and prolonged initiation of coagula-
tion (rapidly detectable by prolonged clotting time), PCC
may be administered to increase thrombin generation
(TG) [15]. However, there is little evidence to support
PCC use in trauma-induced coagulopathy (TIC) [17,18].
Trauma studies in animals have revealed reduced
blood loss and improved survival following PCC adminis-
tration, in comparison with placebo [19-22]. Small clinical
reports have described favorable outcomes when using
PCC either alone or in combination with fibrinogen con-
centrate in trauma patients [15,17,23-26]. However, safety
data following PCC administration unrelated to reversal of
vitamin K antagonists are lacking. In a porcine multiple
trauma model, Grottke et al. reported disseminated intra-
vascular coagulation in four out of nine animals receiving
50 IU/kg bodyweight of PCC [27].
Trauma patients are prone to thromboembolic com-
plications regardless of hemostatic therapy [28,29], and
TG parameters have not been studied following PCC
administration. We hypothesized that PCC increases
thrombin potential in patients with severe bleeding trauma.
We analyzed blood samples from trauma patients admitted
to the AUVA trauma center Salzburg with the aim ofassessing TG parameters upon emergency room (ER)
admission and over the following 7 days. Three groups
of patients were compared: those receiving no coagulation
therapy (NCT group), those treated with fibrinogen con-
centrate only (FC group) and those who received PCC in
combination with fibrinogen concentrate (FC-PCC group).
Materials and methods
This prospective, observational, descriptive cohort study
was performed on plasma samples gathered prospect-
ively from trauma patients admitted to the AUVA
Trauma Center Salzburg, Austria between March 2010
and November 2011. The inclusion criterion was admis-
sion to the ER following full trauma-team activation. The
exclusion criteria were age <18 years, burns, pregnancy
and known coagulation disorders. Informed consent was
obtained from the patients or their relatives. The study
was approved by the local ethics committee (E-1231
Votum), Sebastian-Stief-Gasse 2, 5020, Salzburg, Austria,
with reference number EK-1127-2009.
Coagulation therapy (algorithm-based)
The study population was separated into three cohorts
according to the coagulation therapy received: trauma
patients who received no coagulation therapy (NCT
group), patients treated with fibrinogen concentrate only
(FC group), and patients who received both fibrinogen
concentrate and PCC (FC-PCC group). Coagulation
management was based on our institutional protocol for pa-
tients with bleeding trauma, with treatment determined by
viscoelastic coagulation tests (ROTEM®, Tem International,
Munich, Germany) [30]. Briefly, ROTEM analyses are
performed upon ER admission, during initial operative
treatment and following ICU admission. Fibrinogen
concentrate (Haemocomplettan P, CSL Behring, Marburg,
Germany) is considered as first-line therapy in patients
with impaired fibrin polymerization, that is, a clot ampli-
tude (CA) of <7 mm after 10 minutes running time in the
extrinsically activated test plus cytochalasin D (FIBTEM)
assay (target FIBTEM CA10: 10 to 12 mm). If clotting
time (CT) in the extrinsically activated assay (EXTEM) re-
mains prolonged (>80 sec) following fibrinogen concen-
trate treatment, PCC (Prothromplex Total 600 IE, Baxter,
Vienna, Austria) is administered. For patients with obvi-
ously severe coagulopathy upon admission, immediate
treatment with both fibrinogen concentrate (6 to 8 g) and
PCC (20 to 30 IU/kg bodyweight) is administered. Like
other PCCs, Prothromplex Total is standardized according
to FIX, with each vial containing 600 IU of this coagula-
tion factor [31]. The dose of FII, less well defined by the
package insert, has been reported as 750 IU per vial [31].
Tranexamic acid (TXA; 15 to 20 mg/kg bodyweight for
patients with injury severity score (ISS) >16 and/or severe
shock) was incorporated into our treatment protocol in
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is routinely calculated early at our center, using results
from a computed tomography scan performed within
15 minutes of admission (the potential benefits of early
scanning have been reported separately [33]).
The standard protocol recommends blood sampling as
soon as possible following ER admission. In severely
injured patients, blood is drawn after placement of an
arterial line, whereas in less severe trauma where immedi-
ate invasive blood pressure monitoring is not considered
necessary, blood is collected from venous lines. Blood
samples are also drawn every morning for full blood cell
count and standard coagulation tests until day 7 following
ER admission. Thus, the only procedure in this study
comprising an addition to routine monitoring was the
measurement of TG parameters (using residual plasma
specimens from samples that were collected for routine
tests).
Demographic data, laboratory data, trauma severity
scores such as ISS, Glasgow coma scale (GCS) score and
outcome data were obtained from the electronic trauma
database. In all cases, the attending physician was free to
treat patients at his/her own discretion.
Standard coagulation tests
Citrated blood samples were centrifuged and the fol-
lowing coagulation parameters were assessed: fibrino-
gen concentration (Clauss method: electromechanical
detection using an STA-Compact analyzer (Diagnostics
Stago ASA, Asnieres sur Seine, France); normal range 200
to 450 mg/dL), PT (measured using Sysmex XE-2100,
Roche Diagnostics, Mannheim, Germany; normal range
11 to 16.1 sec), aPTT (measured using Sysmex XE-2100,
Roche Diagnostics; normal range 23.7 to 34.9 sec ) and an-
tithrombin (AT) (normal range 80 to 120%).
Thrombin-related measurements
Citrated blood samples were centrifuged twice at 3,200 g
for 20 minutes, and samples of platelet-poor plasma
(PPP) were frozen at −80°C until analysis. TG was stimu-
lated by tissue factor and measured using the Calibrated
Automated Thrombogram (CAT; Thrombinoscope BV,
Maastricht, The Netherlands).
The PPP samples were thawed in a water bath at 37°C,
and centrifuged for 5 minutes at 10,000 g at room
temperature. The measurements were performed in
duplicate using 96-well plastic plates (Immulon 2HB
clear 96-well, Thermo Electron, Boston, MA, USA), and
all reagents were pre-warmed to 37°C: 20 μl of PPP-
Reagent (Thrombinoscope BV) and 80 μl PPP were added
to each well manually. After a brief incubation, 20 μl of
thrombin substrate and calcium chloride (Fluo-Substrate
and Fluo-Buffer, Thrombinoscope BV) were added auto-
matically. The final concentration in the well was 5 pMfor tissue factor and 4 μM phospholipids. A Fluoroskan
Ascent fluorometer (Thermo Scientific, Waltham, MA,
USA) was used to record continuous generation of
thrombin. Each well was calibrated to a parallel well
with a thrombin calibrator (Thrombin calibrator TS
20.0, Thrombinoscope BV).
The following parameters were recorded: lag time,
peak thrombin generation, time to peak, and endogenous
thrombin potential (ETP). Lag time (sec) was defined as
the period between the addition of calcium and substrate
reagent and the first active thrombin concentration higher
than 10 nmol/L. Peak thrombin generation (nM) was de-
fined as the highest active thrombin concentration during
90 minutes of monitoring. The time to peak was defined
as the period from the start of the reaction until peak
thrombin generation. ETP (area under the curve (AUC),
nM.minutes) was the area under the thrombin concentra-
tion versus time graph, from 1 to 90 minutes.Statistical analysis
For all parameters, normality of the data distribution was
tested using the Kolmogorov-Smirnov test. Normally
distributed results were expressed as mean ± standard
deviation, and those distributed otherwise were expressed
as median and interquartile range (IQR) (25th percentile,
75th percentile). Between-group differences were analyzed
using Student t-test, Mann-Whitney rank sum test,
Newman-Keuls test or Kruskal-Wallis test with Dunn’s
multiple comparison as appropriate. Within-group changes
over time in ETP and AT levels were assessed using the
Newman-Keuls test. Statistical calculations were performed
using GraphPad Prism 5.03 (GraphPad Software, La Jolla,
CA, USA). The level of significance was set at P <0.05.Results
The study population comprised 77 patients, 65 male
and 12 female, with a mean age of 40 ± 15 years. The
mean ISS was 25.6 ± 12.7 and the median GCS was 14 (8
to 15). All patients survived until hospital discharge. No
coagulation therapy was considered necessary in 37
patients (NCT group); 23 patients were treated with
fibrinogen concentrate only (FC-group) and 17 patients
received PCC and fibrinogen concentrate (FC-PCC group).
Demographic and clinical data on admission to the ER
are shown in Table 1. ISS was significantly higher in the
FC-PCC group than in the NCT group (P <0.0001).
ROTEM results upon ER admission are shown in
Table 2. There were consistent trends to suggest that the
speed of clotting was reduced and clot strength was de-
creased in the FC group versus the NCT group, and in the
FC-PCC group versus the FC group. Differences between
the FC-PCC group and the NCT group reached statistical
significance.
Table 1 Clinical and demographic data upon emergency room admission
NCT group FC group FC-PCC group P-values
FC-PCC versus NCT FC-PCC versus FC
ISS 18.8 ± 9.4 29.0 ± 11.0 35.7 ± 13.0 <0.0001 ns
Age, years 46 ± 17 40 ± 14 36 ± 13 0.028 ns
Hb, g/dL 12.8 ± 2.2 12.6 ± 2.0 10.1 ± 2.6 0.0002 0.002
Platelet count × 103/μL 225 ± 59 210 ± 54 191 ± 39 0.0334 ns
PT, sec 13.7 (12.7 to 14.6) 14.6 (13.8 to 15.2) 17.2 ± 3.1 0.0002 0.003
aPTT, sec 26.6 (24.5 to 29.1) 27.9 ± 3.2 34.8 ± 9.9 0.0034 0.0042
AT, % 87 ± 16 83 ± 14 61 ± 15 <0.0001 ns
Fibrinogen, mg/dL 234 (197 to 324) 196 ± 52 163 ± 60 <0.0001 0.0001
pH 7.34 (7.29 to 7.37) 7.35 ± 0.07 7.32 ± 0.08 ns ns
BD, mmol/L 1.9 (0.1 to 3.1) 2.4 (0.8 to 5.2) 5.3 (3.9 to 8.3) 0.0035 0.024
Lactate, mmol/L 2.2 (1.3 to 3.2) 1.8 (1.2 to 3.1) 3.5 (2.3 to 5.5) 0.028 0.014
ISS, injury severity score; Hb, hemoglobin; BD, base deficit; ns, not significant; PT, prothrombin time; aPTT, activated partial thromboplastin time; AT, antithrombin;
NCT group, no coagulation therapy; FC group, fibrinogen concentrate only; FC-PCC group, prothrombin complex concentrate and fibrinogen concentrate.
Data are presented as mean ± standard deviation or median (interquartile range). P-values are derived from t-test or Mann-Whitney U-test; significance
level P <0.05.
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administered to the three patient groups. The FC-PCC
group received a significantly higher dose of fibrinogen
concentrate than the FC group (P = 0.0002). Significantly
more red blood cells and platelet concentrate were
transfused in the FC-PCC group than in the FC group
and NCT group (both P <0.0001). FFP was administered
to only one patient in the FC-PCC group.
TG-related data are depicted in Figure 1. There were
no significant differences between the groups in ETP
upon ER admission but subsequently ETP was signifi-
cantly higher in the FC-PCC group compared with either
the NCT group (days 1 to 4) or the FC group (days 1
to 3). The only statistically significant between-group
differences in peak thrombin generation were observed
on day 1, with a significantly higher value in the FC-PCC
group than in either of the other study groups. Similarly,
with lag time and time to peak, significant between-groupTable 2 ROTEM findings on emergency room admission
NCT group (n = 23) FC group (n = 21) FC-P
EXTEM
CT, sec 58.2 ± 9.5 70.2 ± 21.6
CFT, sec 102.3 ± 29.9 116.0 (96.5 to 160.0) 123
CA10, mm 55.2 ± 6.7 48.1 ± 7.8
FIBTEM
CA10, mm 12.0 (10.0 to 15.0) 8.0 (7.0 to 12.5)
CA10, clot amplitude after 10 minutes running time; CT, clotting time; CFT, clot form
test plus cytochalasin D; NCT group, no coagulation therapy; FC group, fibrinogen con
concentrate. Data are presented as mean ± standard deviation or median (interquartile
P-values are derived from t-test or Mann-Whitney U-test; significance level P <0.05;differences were only seen on day 1 (lower values in the
FC-PCC group than in the NCT group).
Standard coagulation test results are depicted in
Figure 2. Significant between-group differences in PT
and aPTT were observed upon ER admission and over the
following 3 to 4 days. Despite ETP being higher and lag
time and time to peak being shorter in the FC-PCC group,
PT and aPTT were significantly prolonged in this group
compared with either the FC group or the NCT group.
This represents an apparent discrepancy between standard
laboratory parameters and measurement of thrombin
potential.
AT upon ER admission was significantly lower in the
FC-PCC group than in either the FC group or the NCT
group and remained low over the following 3 to 4 days
(Figure 2). However, there were no significant between-
group differences on days 5 to 7. Figure 2 also shows that
the only significant between-group difference in plasmaCC group (n = 17) P-values
FC-PCC versus NCT FC-PCC versus FC
72.6 ± 31.5 0.045 ns
.0 (109.0 to 165.0) 0.001 ns
46.3 ± 9.2 0.001 ns
8.0 (4.3 to 11.8) 0.0094 ns
ation time; EXTEM, extrinsically activated test; FIBTEM, extrinsically activated
centrate only; FC-PCC group, prothrombin complex concentrate and fibrinogen
range).
ns, not significant.
Table 3 Blood transfusion and hemostatic therapy during the first 24 hours after hospital admission
NCT group FC group FC-PCC group P-value
RBC, U 0 (0 to 2) 3 (0 to 5) 8 (6 to 10.5) <0.0001
FFP, U 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) ns
Platelet concentrate, U 0 (0 to 0) 0 (0 to 0) 0 (0 to 1) <0.0001
Fibrinogen concentrate, g 0 (0 to 0) 3 (3 to 5) 8 (5 to 11) 0.0002
PCC, IU 0 (0 to 0) 0 (0 to 0) 2,400 (1,650 to 2,500) nc
RBC, red blood cells; FFP, fresh frozen plasma; nc, not calculated; ns, not significant; PCC, prothrombin complex concentrate; NCT group, no coagulation therapy;
FC group, fibrinogen concentrate only; FC-PCC group, prothrombin complex concentrate and fibrinogen concentrate. Data are presented as median (interquartile
range). P-values are derived from the Kruskal-Wallis test; significance level P <0.05.
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admission, when there was a lower value in the FC-PCC
group than in the NCT group. Similarly, the only dif-
ferences between the FC-PCC group and the other
groups in hemoglobin were on admission to the ER (low
hemoglobin in the FC-PCC group) and day 2 (higherFigure 1 Parameters relating to thrombin generation, from emergenc
was significantly higher over the first 3 to 4 days in the prothrombin comp
gray) compared to the fibrinogen concentrate group (FC group) (light gray
AUC, area under curve. *P <0.05; **P <0.01; ***P <0.001; ****P <0.0001; no i
(Tukey). Student t-test or Mann-Whitney rank sum test was used as appropvalue than the FC group) (Figure 3). Platelet counts were
lower in the FC-PCC group at all time points, although
there were no statistically significant between-group
differences on day 7 (Figure 3).
Relative changes in ETP and AT from ER admission
until day 7 following trauma are depicted in Figure 4. Noy room (ER) admission until day 7. Endogenous thrombin potential
lex concentrate-fibrinogen concentrate group (FC-PCC group) (dark
) and patients receiving no coagulation therapy (NCT group) (white).
ndication = not significant. Data are presented as box and whisker plots
riate for between-group comparisons.
Figure 2 Prothrombin time, activated partial thromboplastin time, fibrinogen concentration and antithrombin activity from emergency
room (ER) admission until day 7. The prothrombin complex concentrate-fibrinogen concentrate group (FC-PCC group) (dark gray) was compared
with the fibrinogen concentrate group (FC group) (light gray) and patients receiving no coagulation therapy (NCT group) (white). *P <0.05; **P <0.01;
***P <0.001; ****P <0.0001; no indication = not significant. Data are presented as box and whisker plots (Tukey). Student t-test or Mann-Whitney rank
sum test was used as appropriate for between-group comparisons.
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the NCT and FC groups, although there was a suggestion
of increased AT levels in the NCT group on days 6 and
7 and an increase over time in both AT and ETP in the
FC group. The only statistically significant changes
versus ER admission were lower AT on day 1 in the FC
group and higher AT on day 7 in the same group.
Temporal changes were more prominent in the FC-
PCC group: ETP increased continually over the first
3 days to reach a level significantly higher than at ER
admission, then returned to baseline over the following
4 days. AT changed little in this group during the first
3 days but subsequently increased to reach levels sig-
nificantly above baseline on days 6 and 7. A prominent
gap between ETP and AT was apparent in the FC-PCC
group between days 1 and 4, but not in the other two
study groups.Discussion
To the best of our knowledge, this is the first study
investigating TG-related parameters following PCC
administration in acute trauma patients. PCC therapy
resulted in significantly higher ETP than in patients
who received fibrinogen concentrate only or no coagula-
tion therapy at all and, importantly, this was sustained
over the first 3 to 4 days following PCC administration.
AT was significantly lower in the FC-PCC group from ER
admission until 3 to 4 days later, reaching a nadir on day
2. Hemostasis relies on a delicate balance between pro-
and anticoagulant factors, and between thrombin potential
and thrombin inhibition potential. This balance may have
been impaired in the FC-PCC group, during a period
when fibrinogen levels were increased above the normal
range; similar findings have been reported in previous
studies [34,35]. The overall picture is increased thrombin
Figure 3 Hemoglobin and platelet count from emergency room
(ER) admission until day 7. The prothrombin complex
concentrate-fibrinogen concentrate group (FC-PCC group) (dark
gray) was compared with the fibrinogen concentrate group (FC
group) (light gray) and patients receiving no coagulation therapy
(NCT group) (white). *P <0.05; **P <0.01; ****P <0.0001; no indication
= not significant. Data are presented as box and whisker plots
(Tukey). Student t-test or Mann-Whitney rank sum test was used as
appropriate for between-group comparisons.
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lation (that is, fibrinogen reaching a plateau on day 4)
and decreased potential for coagulation inhibition (AT
reaching a nadir on day 2). To investigate the potential
prothrombotic risk, we recommend that all future studies
of PCCs - in all indications including warfarin reversal,
new oral anticoagulant reversal and perioperative bleeding -
include assessment of thrombin generation for at least
4 days post-treatment.
A well-established indication for PCC in trauma is the
rapid reversal of oral anticoagulation by vitamin K antago-
nists [36,37]. PCC is licensed in Europe more broadly for
the treatment or prophylaxis of bleeding in acquired defi-
ciency of prothrombin complex coagulation factors. Small
observational studies of PCC in trauma patients suggest
that PCC is useful as a component of hemostatic therapy
in bleeding patients [13-15,23,25,26,36,38]. The Europeantrauma guidelines recommend PCC primarily for emer-
gency reversal of vitamin K-dependent oral anticoagulants
[39]. PCC therapy, guided by thromboelastometric evi-
dence of delayed coagulation initiation, is nevertheless
advocated as part of a strategy based on goal-directed
administration of coagulation factor concentrates [39].
Outside life-threatening bleeding, PCC should only be
administered after fibrinogen supplementation because,
as shown previously, the administration of fibrinogen is
liable to shorten CT [40].
Importantly, the current study demonstrated poor
agreement between TG-related data and standard coagu-
lation tests. Prolonged PT and aPTT suggest deficient
TG in the FC-PCC group when the true thrombin po-
tential, as shown by ETP, is increased. Similar findings
have been reported previously [27,41]; major shortcom-
ings with PT and aPTT include cessation upon formation
of the first fibrin strands when only around 5% of the total
thrombin has been generated, and lack of sensitivity to
anticoagulants such as AT [12,41,42]. TG is not usually
deficient during the early stages of TIC, with evidence
suggesting that it is more likely to be increased
[12,43,44]. There is a risk that standard coagulation pa-
rameters may lead to unnecessary PCC therapy when the
true thrombin potential is adequate, potentially increasing
the patient’s risk of thromboembolism. The use of standard
coagulation tests for guidance of any hemostatic therapy is
therefore highly questionable. EXTEM CT, suggested as a
means of guiding PCC therapy, also appears not be optimal
for this purpose [27]. Improved diagnostic testing, possibly
relating to thrombin potential, is needed to guide PCC
administration to trauma patients.
ETP is strongly dependent on the concentration of
prothrombin (FII), and this has been illustrated by a lin-
ear relationship between prothrombin concentration and
ETP in prothrombin-deficient plasma [45]. Such correl-
ation was not observed for other coagulation factors such
as FV, FVII, FX and FXI. Hanker-Dusel et al. investigated
the ability of different PCC preparations to generate
thrombin in coumadin-treated plasma. The PCC with the
highest content of FII produced the largest amount of
thrombin [46]. These findings have been confirmed in a
rabbit model, where thrombus formation was observed in
all animals receiving high amounts of prothrombin [47].
The long half-life of prothrombin (60 to 72 h) [48] means
that the effects of PCC therapy may potentially last for a
prolonged period of time.
Relative quantities of coagulation factors and inhibitors
differ significantly between different PCC preparations
[49,50], although the ratio of AT to prothrombin is
consistently low [46,49]. AT is the most important inhibitor
of thrombin [46,51,52], meaning that physiological ratios
between prothrombin and AT are needed for normal levels
of TG [46,52]. A substantial increase in FII accompanied by
Figure 4 Relationship between change in endogenous
thrombin potential and change in antithrombin, from
emergency room (ER) admission until day 7 following
trauma. In the FC-PCC group, a pronounced gap between
endogenous thrombin potential and antithrombin was observed.
ETP, endogenous thrombin potential (solid symbols); AT,
antithrombin (open symbols); NCT group (triangles), patients who
received no coagulation therapy; FC group (squares), patients
who received fibrinogen concentrate only; FC-PCC group (circles),
patients who were treated with prothrombin complex concentrate
and human fibrinogen concentrate. *P <0.05; ***P <0.001; not
indicated = not significant (within-group comparison versus ER
admission). Data are presented as median (interquartile range).
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be assumed to increase the risk of thromboembolic com-
plications [52]. Labeling of PCCs according to FII content
has been proposed [46] but, until this is implemented,
physicians are prone to be unaware of the dose of FII with
PCCs and the fact that it exceeds the FIX dose [50]. There
is therefore a risk of excess FII being administered. The
risk may be increased for products with a high FII:FIX
ratio or a similar FII:FIX ratio but higher quantity of FIX
per vial. The need for caution is underlined by the history
of thromboembolic complications with PCC [10], by
animal data indicating risks of thromboemboli and DIC
[27], and by the fact that another thrombin generation
drug, recombinant activated FVII (rFVIIa), has been re-
ported to increase the risk of thromboembolic adverse
events among bleeding patients without hemophilia
[53]. A recent study showing that PCC may improve TG
among neonates undergoing cardiopulmonary bypass also
highlighted the need for caution in relation to prothrom-
botic risk [54].
At a dose of 50 IU/kg, one PCC preparation produced
no clinical evidence of thrombosis in healthy volunteers
[55]. However, unlike in trauma patients, the thrombin
inhibition potential would be normal among both healthy
volunteers and warfarin patients. The safety of PCC in
trauma patients has not yet been established, and it may
be important that the effects upon ETP are variable
between PCCs from different manufacturers [49]. In
principle, there are two options for controlling thrombin
potential following PCC administration. First, AT could be
supplemented [56]; Hanker-Dusel et al. suggested 1:1 as
the optimal administration ratio of AT to FII [46]. The
second option is to minimize the administered dose of
PCC, to generate the minimum increase in thrombin
potential necessary for adequate hemostasis. However,
in acute bleeding this is difficult to achieve and routine,
rapid estimation of thrombin potential is not currently
possible. We have revised our treatment protocol for pa-
tients receiving PCC during the acute treatment phase. As
a new step, the plasma activity of AT is monitored and,
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activity falls below 80% (lower limit of the normal range).
Importantly, we do not administer AT during the acute
bleeding phase due to the potential risk of aggravating
coagulopathy. There is no evidence whether this strategy
will reduce the risk of thromboembolic complications.
However, the concept of AT monitoring/supplementation
in conjunction with PCC has existed for at least 15 years
and it has been advocated by the influential Paul Ehrlich
Institute in Germany [46,57].
The present study points to an important difference
between administration of PCC and fibrinogen con-
centrate as hemostatic therapy. An increasing body of
evidence suggests that the effects of fibrinogen concentrate
are short-lived, with no significant effect on fibrinogen
levels at 24 h and later [58-60]. In contrast, the effects of
PCC on thrombin potential appear to last for 4 days post
treatment. This duration of effect is consistent with the
approximate 60-hour half-life of FII. Studies involving
high-dose fibrinogen concentrate or a high baseline/target
fibrinogen concentration have consistently shown the
lack of a safety signal [59,61-63]. Conversely, studies of
thrombin generating drugs including PCCs have indi-
cated the potential for increased risk of thromboembolic
complications [27,46,64]. These data provide a rationale
for supplementing fibrinogen first and prothrombin com-
plex coagulation factors second.
Limitations
This study of hemostatic therapy with PCC lacked a com-
parator group of patients with the same characteristics
(for example, ISS) receiving alternative treatment, such as
FFP. Hemostatic therapy was administered in accordance
with the criteria documented in the treatment algorithm
used at our center [30]. As a result, patients in the differ-
ent study groups had differing characteristics/severity of
coagulopathy, meaning that differences in outcomes may
not have been caused solely by the treatments defining the
study groups. However, the primary result (significantly
higher ETP in the FC-PCC group than in the other patient
groups) can be attributed to PCC administration.
Fluid therapy, either in the pre-hospital phase or during
the course of initial care, was not evaluated. High-volume
fluid therapy results in dilution of both coagulation factors
and inhibitors, but not necessarily to the same extent.
Thrombin generation has been reported to increase step-
wise with increasing hemodilution up to a dilution level of
40%, and to remain above baseline to a dilution level of
80% [43]. This is attributable to a greater decrease in
coagulation inhibitors, particularly AT, compared with
coagulation factors [43,51]. Assuming that the FC-PCC
group comprised patients with more severe bleeding
than the other patient groups, larger quantities of fluid
are likely to have been administered. The amount offluid and its impact on thrombin generation among our
patients is unclear, but the assumed increased dilution in
the FC-PCC group may have contributed to the lower
levels of AT.
Hemostatic therapy was administered according to
ROTEM findings, in accordance with the treatment
algorithm [30]. Unfortunately, because the focus of this
study was on thrombin generation, we did not collect
ROTEM data immediately before and after treatment.
ROTEM data are only available for the ER admission
time point, and most hemostatic treatment was admin-
istered later. Therefore the ROTEM data presented in
Table 2 do not represent the values that triggered
treatment with PCC or other hemostatic agents.
Assessment of TG in vitro using tissue factor as the
activator does not necessarily provide accurate represen-
tation of the in vivo pattern of TG, because physiological
conditions are not represented. Uncertainty in this regard
is increased by the fact that ETP was the only thrombin-
related parameter demonstrating a significant increase in
the FC-PCC group over the first 3 to 4 days - other
thrombin-related parameters sowed significant between-
group differences only on day 1. We did not measure
levels of thrombin-antithrombin complex or prothrombin
fragments F1 and F2, and these could have provided fur-
ther insight into the status in vivo.
The lack of clinical endpoints in this study means that
the implications of our results for patient outcomes can-
not be deduced. We do not routinely screen our patients
for deep vein thrombosis, in accordance with American
College of Chest Physicians guidelines [65]. Therefore,
the data needed to analyze thromboembolic events in
the present patient cohort are not available. A study of
the effects of PCC administration on thromboembolism
among trauma patients is clearly warranted. Considering
that thromboembolism is reported as a low-frequency
complication of PCC therapy [66], a large sample size
would be needed (perhaps ten times the number of
patients included in the present study). Furthermore, the
post-treatment follow-up period for such a study would
be around 4 weeks.
Conclusion
PCC administration for hemostatic therapy in major
trauma patients with bleeding results in a significant
increase in ETP, sustained for several days. Postoperative
increases in fibrinogen levels were observed in all study
groups, while patients receiving PCC therapy had lower
levels of AT than those treated solely with fibrinogen
concentrate. These findings imply a pro-thrombotic
state among PCC recipients but this was not indicated
by standard coagulation tests. Randomized controlled
trials with clinical endpoints are needed to understand the
significance of our results and to evaluate the efficacy and
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become available, we recommend careful use of PCC in
this setting: administer PCC only to bleeding patients
with obviously severe coagulopathy upon admission or
prolonged EXTEM CT after fibrinogen supplementation;
adhere to the dose ranges specified in the published algo-
rithm [30]; and monitor and potentially supplement AT
among PCC recipients.
Key messages
 PCC may be useful as haemostatic therapy for
patients with bleeding trauma requiring increased
thrombin generation
 This study shows that PCC administration according
to a concentrate-based treatment algorithm was
associated with significantly increased endogenous
thrombin potential and lower antithrombin levels
than in unmatched controls
 The results imply a pro-thrombotic state among
PCC recipients, but this was not evident from
standard coagulation test results (PT, aPTT)
 Randomized controlled trials are needed to ascertain
the implications of our findings for patient outcomes,
and to characterize the safety and efficacy of PCC
among patients with trauma-induced bleeding
 Before robust evidence becomes available, we
recommend careful use of PCC in this setting
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